Project Grant R43DA062234
Award Date
9/1/25
Completion Date
8/31/26
Dollars Obligated
$307K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
New York, NY 10023, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess the practicality of a closed-loop medication management system for opioid pain management targeting ambulatory patients with extremity fractures being discharged from the emergency department. The key objectives are to adapt the Addinex system to seamlessly integrate with hospital...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded Labsys LLC a $643,948 Project Grant to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, pain-free patch that can monitor medication levels in the interstitial fluid and provide real-time insights into the effectiveness of opioid use disorder treatment protocols. In Phase I, Labsys will engineer an...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop, refine, and evaluate a customized version of their "MyTrials" integrated remote biomarker capture system for decentralized clinical trials (DCTs) focused on substance use disorders (SUDs). The project aims to address key methodological limitations of DCTs for SUDs by creating a product...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $400,000 Project Grant to Iontx Inc., a woman-owned small business located in Friendswood, Texas. The goal of this 12-month grant, which runs from May 15, 2025 to April 30, 2026, is to conduct structure-activity relationship (SAR) analysis and optimization of a novel small-molecule compound, 5788, that enhances the FGF13/NAV1.6 complex. This compound has shown potential to...
The National Institute on Drug Abuse (NIDA) awarded a $326,410 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Berkshire Biomedical Corporation in Dallas, TX. The grant will fund a two-phased clinical study to evaluate the feasibility, acceptance, and impact on treatment retention of a hand-held, automated, personalized oral liquid dispensing system (COPA) for delivering take-home methadone to patients with opioid use disorder. The initial single-site pilot...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,088,999 Project Grant to The Trustees of Columbia University in the City of New York, effective August 15, 2024 through May 31, 2029. The objective of this project is to develop efficient statistical estimators for analyzing data fusion of multi-study, multi-outcome clinical trials for treating opioid use disorder. The project aims to: 1) create parametric and...
This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...
The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a rapid fingerstick diagnostic test for opioid and stimulant use disorders. This project aims to address the escalating public health crisis of opioid and stimulant overdose deaths in the United States, which reached over 107,000 in...